EA201391485A1 - Способы и композиции для лечения нейродегенеративных заболеваний - Google Patents

Способы и композиции для лечения нейродегенеративных заболеваний

Info

Publication number
EA201391485A1
EA201391485A1 EA201391485A EA201391485A EA201391485A1 EA 201391485 A1 EA201391485 A1 EA 201391485A1 EA 201391485 A EA201391485 A EA 201391485A EA 201391485 A EA201391485 A EA 201391485A EA 201391485 A1 EA201391485 A1 EA 201391485A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
methods
treatment
neurodegenerative diseases
solvate
Prior art date
Application number
EA201391485A
Other languages
English (en)
Inventor
Уилльям К. Шекспир
Фрэнк Дж. Халуска
Original Assignee
Ариад Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ариад Фармасьютикалз, Инк. filed Critical Ариад Фармасьютикалз, Инк.
Publication of EA201391485A1 publication Critical patent/EA201391485A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

В изобретении раскрыты способы и композиции для лечения или предотвращения нейродегенеративного заболевания путем введения соединения формулы Iили его фармацевтически приемлемой соли, сольвата или гидрата, где переменные определены в описании изобретения.
EA201391485A 2011-04-07 2012-04-06 Способы и композиции для лечения нейродегенеративных заболеваний EA201391485A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472961P 2011-04-07 2011-04-07
US201161518427P 2011-05-05 2011-05-05
PCT/US2012/032566 WO2012139027A1 (en) 2011-04-07 2012-04-06 Methods and compositions for treating neurodegenerative diseases

Publications (1)

Publication Number Publication Date
EA201391485A1 true EA201391485A1 (ru) 2014-03-31

Family

ID=46969573

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391485A EA201391485A1 (ru) 2011-04-07 2012-04-06 Способы и композиции для лечения нейродегенеративных заболеваний

Country Status (11)

Country Link
US (1) US20140045826A1 (ru)
EP (1) EP2694064A1 (ru)
JP (1) JP2014510154A (ru)
KR (1) KR20140022063A (ru)
CN (1) CN103582478A (ru)
AU (1) AU2012240026A1 (ru)
BR (1) BR112013024171A2 (ru)
CA (1) CA2832483A1 (ru)
EA (1) EA201391485A1 (ru)
MX (1) MX2013011591A (ru)
WO (1) WO2012139027A1 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1973545T3 (pl) 2005-12-23 2013-05-31 Ariad Pharma Inc Bicykliczne Związki Heteroarylowe
WO2013170774A1 (zh) * 2012-05-16 2013-11-21 上海医药集团股份有限公司 具有抗肿瘤活性的乙炔衍生物
CA2815506C (en) 2012-12-12 2018-12-11 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
AU2013204506B2 (en) * 2012-12-13 2016-05-05 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
US20140343282A1 (en) 2013-05-16 2014-11-20 Apicore, Llc Processes for making ponatinib and intermediates thereof
CN104341416B (zh) * 2013-07-31 2017-03-29 南京圣和药业股份有限公司 蛋白酪氨酸激酶抑制剂及其应用
WO2015085971A1 (en) * 2013-12-09 2015-06-18 Zentiva, K.S. Hydrobromide salt of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide
CN104496995A (zh) * 2014-01-06 2015-04-08 广东东阳光药业有限公司 制备3-乙炔基咪唑并[1,2-b]哒嗪的方法
GB2522226A (en) * 2014-01-17 2015-07-22 Agency Science Tech & Res Heteroaryl alkyne derivatives and uses thereof
CN106146391A (zh) * 2015-04-15 2016-11-23 中国科学院上海药物研究所 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途
ES2921257T3 (es) * 2016-06-20 2022-08-22 Daegu Gyeongbuk Medical Innovation Found Nuevo derivado de imidazopiridina, procedimiento para prepararlo y composición farmacéutica que contiene el mismo como ingrediente activo para prevenir o tratar el cáncer
US11117883B2 (en) * 2016-12-15 2021-09-14 Ariad Pharmaceuticals, Inc. Benzimidazole compounds as c-Kit inhibitors
CN108399315B (zh) * 2018-03-01 2022-02-22 中国科学院长春应用化学研究所 一种Bcr-Abl蛋白激酶抑制剂的筛选方法
CN110272426B (zh) 2018-07-17 2022-05-31 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基（杂）芳环类化合物
WO2020191091A1 (en) 2019-03-19 2020-09-24 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic aza-benzothiophene and aza-benzofuran compounds
WO2020223235A1 (en) * 2019-04-29 2020-11-05 Incyte Corporation Mini-tablet dosage forms of ponatinib
AU2020292703A1 (en) 2019-06-11 2022-01-27 Sun Pharma Advanced Research Company Ltd. Treatment for synucleinopathies
CR20220665A (es) 2020-05-29 2023-07-19 Boehringer Ingelheim Pharma Compuestos heterocíclicos como anthelmínticos
GB202019874D0 (en) * 2020-12-16 2021-01-27 Benevolentai Bio Ltd New compounds and methods
WO2022225972A1 (en) * 2021-04-19 2022-10-27 Oregon Health & Science University Compounds with improved cardiac safety for the treatment of cancer and neurodegenerative disorders
AU2022377394A1 (en) 2021-11-01 2024-06-13 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic pyrrolopyridazine compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248168A1 (en) * 2003-03-25 2004-12-09 Wei Liu Novel brain-localized protein kinases homologous to homeodomain-interacting protein kinases
PL1973545T3 (pl) * 2005-12-23 2013-05-31 Ariad Pharma Inc Bicykliczne Związki Heteroarylowe

Also Published As

Publication number Publication date
BR112013024171A2 (pt) 2016-12-13
EP2694064A1 (en) 2014-02-12
US20140045826A1 (en) 2014-02-13
MX2013011591A (es) 2014-04-14
CA2832483A1 (en) 2012-10-11
WO2012139027A1 (en) 2012-10-11
JP2014510154A (ja) 2014-04-24
CN103582478A (zh) 2014-02-12
KR20140022063A (ko) 2014-02-21
AU2012240026A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
EA201391485A1 (ru) Способы и композиции для лечения нейродегенеративных заболеваний
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
PH12016501750A1 (en) Human plasma kallikrein inhibitors
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
NZ712207A (en) Tetrahydropyrrolothiazine compounds
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
EA201391615A1 (ru) Дейтерированные потенциаторы cftr
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
EA201101507A1 (ru) Способы лечения солидных опухолей
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
EA201692300A1 (ru) Производные карбоксамида
PH12016501198A1 (en) Compounds and compositions for the treatment of parasitic diseases
MX2019002369A (es) Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial.
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201270347A1 (ru) Производные апогоссиполона в качестве противоопухолевых агентов
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний